HomeCompareSSUMY vs JNJ

SSUMY vs JNJ: Dividend Comparison 2026

SSUMY yields 1.15% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SSUMY wins by $39.2K in total portfolio value
10 years
SSUMY
SSUMY
● Live price
1.15%
Share price
$39.10
Annual div
$0.45
5Y div CAGR
54.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$69.4K
Annual income
$21,405.82
Full SSUMY calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — SSUMY vs JNJ

📍 SSUMY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSSUMYJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SSUMY + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SSUMY pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SSUMY
Annual income on $10K today (after 15% tax)
$98.03/yr
After 10yr DRIP, annual income (after tax)
$18,194.95/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, SSUMY beats the other by $14,208.96/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SSUMY + JNJ for your $10,000?

SSUMY: 50%JNJ: 50%
100% JNJ50/50100% SSUMY
Portfolio after 10yr
$49.9K
Annual income
$13,047.61/yr
Blended yield
26.17%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

SSUMY
No analyst data
Altman Z
1.7
Piotroski
6/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SSUMY buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSSUMYJNJ
Forward yield1.15%2.13%
Annual dividend / share$0.45$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR54.2%28%
Portfolio after 10y$69.4K$30.3K
Annual income after 10y$21,405.82$4,689.40
Total dividends collected$45.5K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SSUMY vs JNJ ($10,000, DRIP)

YearSSUMY PortfolioSSUMY Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$10,878$177.84$10,592$272.30+$286.00SSUMY
2$11,918$278.79$11,289$357.73+$629.00SSUMY
3$13,193$440.19$12,123$472.89+$1.1KSSUMY
4$14,818$702.21$13,141$629.86+$1.7KSSUMY
5$16,992$1,136.67$14,408$846.81+$2.6KSSUMY
6$20,060$1,878.40$16,021$1,151.60+$4.0KSSUMY
7$24,660$3,195.74$18,122$1,588.22+$6.5KSSUMY
8$32,048$5,661.52$20,930$2,228.20+$11.1KSSUMY
9$44,894$10,603.21$24,792$3,191.91+$20.1KSSUMY
10$69,443$21,405.82$30,274$4,689.40+$39.2KSSUMY

SSUMY vs JNJ: Complete Analysis 2026

SSUMYStock

Sumitomo Corporation engages in general trading business worldwide. It operates through six segments: Metal Products; Transportation & Construction Systems; Infrastructure; Media & Digital; Living Related & Real Estate; and Mineral Resources, Energy, Chemical & Electronics. The company provides steel sheets and tubular products; and manufactures, leases, sells, services, and finances ships, aircrafts, motor vehicles, construction equipment, and components and parts. It is also involved in the development of renewable energy projects comprising power generation and power plant engineering, procurement, and construction activities; electricity retail; industrial facilities and equipment, water, transportation systems and infrastructure, airports, smart city project, environmental solutions, and storage battery businesses; development and operation of industrial parks; arranging insurance; and provision of logistics services. In addition, the company engages in the cable television, 5G related technologies, programming distribution, movies, digital media and video content, TV shopping, and e-commerce businesses; cell phone, ICT platform, digital solution, and venture capital businesses; provision of smart communications infrastructure; operation of food supermarkets and drugstore chains; trade of cement and building materials; and real estate businesses. Further, it develops and trades in coal, iron ore, manganese, uranium, non-ferrous and precious metals, petroleum, natural gas and liquefied natural gas, and commodity derivative transactions; trades in non-ferrous metal products, liquefied petroleum gas, storage batteries, carbon products, plastics, organic and inorganic chemicals, silicon wafers, LEDs, pharmaceuticals, agricultural chemicals, household insecticides, fertilizers, and veterinary drugs; engages in the investing activities; and provides electronics manufacturing services. The company was incorporated in 1919 and is headquartered in Tokyo, Japan.

Full SSUMY Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this SSUMY vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SSUMY vs SCHDSSUMY vs JEPISSUMY vs OSSUMY vs KOSSUMY vs MAINSSUMY vs ABBVSSUMY vs MRKSSUMY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.